Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Oct 6

PMID 33019553

Citations 21

Authors

Rachele Adorisio

Erica Mencarelli

Nicoletta Cantarutti

Camilla Calvieri

Liliana Amato

Marianna Cicenia

Massimo Silvetti

Adele DAmico

Maria Grandinetti

Fabrizio Drago

Antonio Amodeo

Affiliations

Soon will be listed here.

Abstract

Duchenne muscular dystrophy (DMD) cardiomyopathy (DCM) is characterized by a hypokinetic, dilated phenotype progressively increasing with age. Regular cardiac care is crucial in DMD care. Early recognition and prophylactic use of angiotensin converting enzyme inhibitors (ACEi) are the main stay therapeutic strategy to delay incidence of DMD-DCM. Pharmacological treatment to improve symptoms and left ventricle (LV) systolic function, have been widely implemented in the past years. Because of lack of DMD specific drugs, actual indications for established DCM include current treatment for heart failure (HF). This review focuses on current HF strategies to identify, characterize, and treat DMD-DCM.

Citing Articles

Early Cardiac Dysfunction in Duchenne Muscular Dystrophy: A Case Report and Literature Update.

Lupu M, Pintilie I, Teleanu R, Marin G, Vladacenco O, Severin E Int J Mol Sci. 2025; 26(4).

PMID: 40004149 PMC: 11855830. DOI: 10.3390/ijms26041685.

Unraveling the Genetic Heartbeat: Decoding Cardiac Involvement in Duchenne Muscular Dystrophy.

Novelli V, Canonico F, Laborante R, Manzoni M, Arcudi A, Pompilio G Biomedicines. 2025; 13(1).

PMID: 39857686 PMC: 11762982. DOI: 10.3390/biomedicines13010102.

Prophylactic Use of Cardiac Medications and Survival in Duchenne Muscular Dystrophy.

Conway K, Thomas S, Neyaz T, Ciafaloni E, Mann J, Staron-Ehlinger M Muscle Nerve. 2025; 71(4):574-582.

PMID: 39853770 PMC: 11887528. DOI: 10.1002/mus.28353.

Disturbed Atrial Conduction in Patients with Duchenne Muscular Dystrophy.

Turan O, Kocabas A Anatol J Cardiol. 2024; .

PMID: 39292155 PMC: 11460553. DOI: 10.14744/AnatolJCardiol.2024.4599.

High mobility group box 1 (HMGB1) is a potential disease biomarker in cell and mouse models of Duchenne muscular dystrophy.

Slick R, Sutton J, Haberman M, OBrien B, Tinklenberg J, Mardikar A Biol Open. 2024; 13(9).

PMID: 39158383 PMC: 11391821. DOI: 10.1242/bio.060542.

References

Rose E, Gelijns A, Moskowitz A, Heitjan D, Stevenson L, Dembitsky W . Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2002; 345(20):1435-43. DOI: 10.1056/NEJMoa012175. View

Olivieri L, Kellman P, McCarter R, Cross R, Hansen M, Spurney C . Native T1 values identify myocardial changes and stratify disease severity in patients with Duchenne muscular dystrophy. J Cardiovasc Magn Reson. 2016; 18(1):72. PMC: 5084339. DOI: 10.1186/s12968-016-0292-8. View

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View

Kellman P, Bandettini W, Mancini C, Hammer-Hansen S, Hansen M, Arai A . Characterization of myocardial T1-mapping bias caused by intramyocardial fat in inversion recovery and saturation recovery techniques. J Cardiovasc Magn Reson. 2015; 17:33. PMC: 4425910. DOI: 10.1186/s12968-015-0136-y. View

Matsumura T, Tamura T, Kuru S, Kikuchi Y, Kawai M . Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. Intern Med. 2010; 49(14):1357-63. DOI: 10.2169/internalmedicine.49.3259. View

Patrianakos A, Zacharaki A, Kalogerakis A, Solidakis G, Parthenakis F, Vardas P . Two-dimensional global and segmental longitudinal strain: are the results from software in different high-end ultrasound systems comparable?. Echo Res Pract. 2015; 2(1):29-39. PMC: 4676462. DOI: 10.1530/ERP-14-0070. View

Buyse G, Goemans N, Van den Hauwe M, Thijs D, de Groot I, Schara U . Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul Disord. 2011; 21(6):396-405. DOI: 10.1016/j.nmd.2011.02.016. View

Madigan J, Barbone A, Choudhri A, Morales D, Cai B, Oz M . Time course of reverse remodeling of the left ventricle during support with a left ventricular assist device. J Thorac Cardiovasc Surg. 2001; 121(5):902-8. DOI: 10.1067/mtc.2001.112632. View

Meyers T, Townsend D . Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy. Int J Mol Sci. 2019; 20(17). PMC: 6747383. DOI: 10.3390/ijms20174098. View

10.

Wexberg P, Avanzini M, Mascherbauer J, Pfaffenberger S, Freudenthaler B, Bittner R . Myocardial late gadolinium enhancement is associated with clinical presentation in Duchenne muscular dystrophy carriers. J Cardiovasc Magn Reson. 2016; 18(1):61. PMC: 5034448. DOI: 10.1186/s12968-016-0281-y. View

11.

Spurney C, McCaffrey F, Cnaan A, Morgenroth L, Ghelani S, Gordish-Dressman H . Feasibility and Reproducibility of Echocardiographic Measures in Children with Muscular Dystrophies. J Am Soc Echocardiogr. 2015; 28(8):999-1008. PMC: 4526320. DOI: 10.1016/j.echo.2015.03.003. View

12.

Perri G, Filippelli S, Adorisio R, Iacobelli R, Iodice F, Testa G . Left ventricular assist device as destination therapy in cardiac end-stage dystrophinopathies: Midterm results. J Thorac Cardiovasc Surg. 2016; 153(3):669-674. DOI: 10.1016/j.jtcvs.2016.08.016. View

13.

Slaughter M, Rogers J, Milano C, Russell S, Conte J, Feldman D . Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009; 361(23):2241-51. DOI: 10.1056/NEJMoa0909938. View

14.

Fayssoil A, Ben Yaou R, Ogna A, Chaffaut C, Leturcq F, Nardi O . Left bundle branch block in Duchenne muscular dystrophy: Prevalence, genetic relationship and prognosis. PLoS One. 2018; 13(1):e0190518. PMC: 5755816. DOI: 10.1371/journal.pone.0190518. View

15.

Silva Enciso J . Mechanical Circulatory Support: Current Status and Future Directions. Prog Cardiovasc Dis. 2016; 58(4):444-54. DOI: 10.1016/j.pcad.2016.01.006. View

16.

Feudtner C . Collaborative communication in pediatric palliative care: a foundation for problem-solving and decision-making. Pediatr Clin North Am. 2007; 54(5):583-607, ix. PMC: 2151773. DOI: 10.1016/j.pcl.2007.07.008. View

17.

Fayssoil A, Abasse S, Silverston K . Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2017; 4(1):17-23. PMC: 5345647. DOI: 10.3233/JND-160194. View

18.

Kilic A, Acker M, Atluri P . Dealing with surgical left ventricular assist device complications. J Thorac Dis. 2016; 7(12):2158-64. PMC: 4703654. DOI: 10.3978/j.issn.2072-1439.2015.10.64. View

19.

Amedro P, Vincenti M, De La Villeon G, Lavastre K, Barrea C, Guillaumont S . Speckle-Tracking Echocardiography in Children With Duchenne Muscular Dystrophy: A Prospective Multicenter Controlled Cross-Sectional Study. J Am Soc Echocardiogr. 2019; 32(3):412-422. DOI: 10.1016/j.echo.2018.10.017. View

20.

Palladino A, Papa A, Morra S, Russo V, Ergoli M, Rago A . Are there real benefits to implanting cardiac devices in patients with end-stage dilated dystrophinopathic cardiomyopathy? Review of literature and personal results. Acta Myol. 2019; 38(1):1-7. PMC: 6598406. View